Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Bevacizumab + Chemotherapy in Cervical Cancer
NCT05247619Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Cervical Cancer (CC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05247619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247619.